Trial Profile
Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Chondrosarcoma
- Focus Therapeutic Use
- 18 Aug 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2026.
- 18 Aug 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2026.
- 28 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.